sentence_eng_Latn: “The EU approval of Perjeta is the result of years of research into the HER2 pathway and we are excited to offer a new treatment option for people with this aggressive disease,” said Hal Barron, M.D., Chief Medical Officer and Head, Global Product Development. “The combination of Perjeta, Herceptin
sentence_wol_Latn: “Naŋgu ub Perjeta bu UE njureef u ay at u gëstu ci yoonu HER2 te beg nañu di leen yegal tanneef u paj bu bees ngir nit ñi feebar bu soxor bii dal”, nee Hal Barron, Kilifë ci Paj mi te it doon bopp ba, Suqqali Garab bu Yaatu. Mbootaayu Perjeta, Herceptin